BiotechTube
NS Pharma

NS Pharma

Paramus, United States· Est.
nspharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $80M

Overview

NS Pharma is a private, clinical-stage biotech subsidiary of Japan's Nippon Shinyaku, headquartered in Paramus, New Jersey. The company is dedicated to advancing therapies for rare diseases, with a pipeline centered on exon-skipping oligonucleotides for Duchenne Muscular Dystrophy and a JAK1 inhibitor for eosinophilic granulomatosis with polyangiitis (EGPA). Its lead asset, brogidirsen (NS-089/NCNP-02), has reported multi-year clinical data, positioning the company in the competitive DMD landscape, while its platform extends to cell therapy research. NS Pharma operates as a strategic R&D arm, likely funded by its parent company, with a patient-centric mission driven by innovative science.

Neurological DiseasesInflammatory Diseases

Technology Platform

Exon-skipping oligonucleotides for DMD; Selective JAK1 inhibition for inflammatory diseases; Exploration of cell therapy.

Funding History

2
Total raised:$80M
Series B$50M
Series A$30M

Opportunities

The significant unmet need in Duchenne Muscular Dystrophy and other rare diseases allows for premium pricing and strong regulatory support.
Success with its exon-skipping or JAK1 platforms could enable expansion into additional indications, leveraging the core technology.
As the U.S.
subsidiary of Nippon Shinyaku, it is well-positioned to commercialize products in the world's largest pharmaceutical market.

Risk Factors

Intense competition in the DMD space from approved and pipeline therapies poses a major commercial threat.
Clinical development risks remain high, as demonstrating definitive functional benefit for rare disease drugs is challenging.
As a pre-revenue company reliant on parent funding, its valuation and autonomy are contingent on continued pipeline success.

Competitive Landscape

In DMD, NS Pharma competes directly with Sarepta Therapeutics (market leader in exon-skipping) and Pfizer (gene therapy). In EGPA, it faces competition from GSK's mepolizumab and other inflammatory disease players developing JAK inhibitors. Differentiation will require superior efficacy, safety, or convenience data.

More companies in Small Molecule Drugs →More companies in United States →